ARS Pharmaceuticals (SPRY) CLO Fitzpatrick Sells $34K of Stock

ARS Pharmaceuticals Chief Legal Officer Sells Shares

Alexander Fitzpatrick, the Chief Legal Officer of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), sold 3,355 shares of the company on June 12, 2026. The transaction was executed at a price of $10.00 per share, resulting in a total value of $33,550. According to a filing with the Securities and Exchange Commission, the sale was carried out under a pre-arranged Rule 10b5-1 trading plan.

SPRY Stock Price and Range Context

Trading near $9.76, SPRY shares sit well below their 52-week peak of $13.15 while holding above the 52-week low of $4.07. The timing of this sale places it months ahead of the company's next scheduled financial update in late autumn, giving market participants plenty of time to weigh leadership moves against the broader biopharmaceutical landscape.

Recent Insider Transactions at ARS Pharmaceuticals

While the legal officer trimmed a small holding, a heavy wave of open-market buying swept through the leadership team shortly after. On June 24, 2026, insider Phillip Schneider acquired 30,000 shares. On that same day, Pratik Shah bought 30,000 shares, Saqib Islam picked up 30,000 shares, and Brent Saunders added 30,000 shares. Laura Shawver also bought 30,000 shares, while Peter Thompson acquired 30,000 shares to round out the coordinated purchases.

Analysts Set New Price Targets

Wall Street firms maintain an active dialogue on the biotech developer, backed by a consensus rating of strong buy among four analysts. On June 25, 2026, Leerink Partners maintained an Outperform rating while adjusting its price target to $24.00 from $25.00. Later, on August 13, 2026, Leerink Partners again maintained its Outperform rating, setting a price target of $18.00. Across the covering firms, the average analyst price target rests at $22.50.

Inside the Business

ARS Pharmaceuticals is a San Diego-based biopharmaceutical firm focused on creating needle-free epinephrine treatments for severe allergic reactions. Its flagship development, neffy, provides a nasal delivery option for emergency allergy care. This operational focus underpins the broader market interest as leadership navigates the path toward commercial expansion.

What's Ahead for ARS Pharmaceuticals, Inc.

Observers will monitor upcoming disclosures and the next earnings report scheduled for November 10, 2026, for further insight into the firm's financial trajectory. Insider transactions remain subject to pre-arranged schedules and personal portfolio strategies rather than acting as standalone market signals.